Background: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1a and 2a. In a phase Ib/2 trial, CRLX101 þ bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101 þ bevacizumab versus standard of care (SOC) in refractory mRCC.
Introduction
Targeted therapies constitute the mainstay of care for treatment of metastatic renal cell cancer (RCC), particularly the most common variant clear cell RCC (ccRCC) [1] . The successful development of antiangiogenesic agents owed to the understanding that functional loss of the von Hippel-Lindau gene VHL raises levels of hypoxia inducible factors (HIF1a and HIF2a) [2] . While the best described downstream target of HIF, the vascular endothelial growth factor (VEGF), has been exploited as a therapeutic target, benefit from VEGF-directed agents is typically of limited duration due to acquired resistance. Plausible mediators include other transcriptional HIF effectors [3] . Patients are then sequenced over to other tyrosine kinase inhibitors (TKI), programmed death 1 (PD1)-directed therapy or inhibitors of the mammalian target of rapamycin (mTOR) [1] . Only one phase III study has looked specifically into third-line patients, unfortunately without meeting its primary end point. [4] CRLX101 is an investigational nanoparticle-drug conjugate (NDC) composed of a cyclodextrin-based polymer backbone linked to camptothecin, an inhibitor of topoisomerase-1, leading to modulation of HIF1a/HIF2a levels in preclinical models [5, 6] . Based on its size and capacity to self-assemble the drug accumulates in tumor tissue, where the payload is gradually released inside tumor cells as its linkage is hydrolyzed [7, 8] . This mechanism limits systemic exposure, while maximizing local effect on tumor tissue. In preclinical models antiangiogenic effects were shown across various solid tumor malignancies [5, 9, 10] . CRLX101 has demonstrated preclinical synergism with bevacizumab [6, 11] . A recent phase I/II investigator-initiated study of CRLX101 plus bevacizumab in RCC with a median two prior lines of therapy confirmed a manageable safety profile and encouraging efficacy with an objective response rate (ORR) of 23% [12] . This prompted development of this randomized phase II trial targeting the third-/fourth-line setting. In the absence of a defined standard in this space, it was decided to compare the new regimen to 'best standard practice', allowing any approved agent not previously employed in the same patient.
Methods Patients
Patients were recruited across 34 centers in the United States and Korea. Eligible subjects were 18þ years of age with ECOG 0-1 performance status and life expectancy of > 3 months. Patients had metastatic RCC of any histologic subtype; they had to have received 2-3 prior lines of molecularly targeted therapy, including 1 VEGF-inhibiting regimen. Prior bevacizumab or topoisomerase-1 inhibitor therapy was not permitted. Stable central nervous system involvement did not preclude patients from study participation. Adequate organ and marrow function were defined in the study protocol. All patients provided written consent.
Study design and treatment
This was an industry-sponsored, open-label, phase II trial randomizing patients 1 : 1 to receive either CRLX101 plus bevacizumab or any regimen considered 'standard of care' (SOC), per treating investigator. SOC options included approved TKI (e.g. axitinib, sorafenib, sunitinib) and rapalogs (e.g. everolimus, temsirolimus) provided the drug had not previously been received.
Patients on the investigational arm received treatment on days 1 and 15 of a 28-day cycle (CRLX10115 mg/m 2 i.v.; bevacizumab 10 mg/kg i.v.). To decrease the risk of CRLX101-induced cystitis, patients received 1000 ml of normal saline i.v. before and after treatment. Premedication included a systemic corticosteroid, H1 and H2 antagonist. Guidance for dose delays and dose modification of CRLX101 was provided in the protocol; attenuated dose levels included 12 and 9 mg/m 2 every 14 days, with concurrent bevacizumab 10 mg/kg.
Subjects randomized to SOC were treated per the manufacturer's label and institutional standards, including dose adjustments. Patients who required dose reductions beyond 50% were withdrawn from study.
Disease extent was assessed every 8 weeks with independent radiological review per Response Evaluation Criteria in Solid Tumors guidelines (RECIST) version 1.1 [13] . Treatment was continued until disease progression or treatment intolerance; cross-over was not permitted. The study was performed in accordance with the protocol, the Declaration of Helsinki, the ICH Harmonized Tripartite Guideline for Good Clinical Practice, and applicable local regulatory requirements.
Statistical plan
The primary end point of the trial was comparison of median progression-free survival (PFS) in patients with clear cell metastatic RCC treated with CRLX101þ bevacizumab versus SOC per independent radiological review. The sample size provided 80% power to detect an increase in median PFS from 3.5 to 5.8 months using the log-rank test statistics with one-sided alpha-level of 0.10. The efficacy projection of 3.5 months median PFS for SOC is consistent with prior third-line data [4] . To detect this difference, equivalent to a hazard ratio of 0.602, 90 ccRCC patients were to be enrolled (45 patients in each group). Up to 20 non-clear cell RCC patients were added for a total of 110 patients. At least 70 total events had to be observed among the ccRCC patients in order to achieve this power. PFS was calculated by Kaplan-Meier method; comparison between the treatment arms were made with stratified log-rank test and Cox proportional hazards model. Randomization was based on a random permuted block assignment; stratification factors included mTOR inhibitor as a prior line of therapy (yes/no), two versus three prior lines of therapy, and non-clear cell RCC histology (yes/no). Patients who discontinued treatment for reasons other than radiographic progression or were lost to follow-up with missing response data were censored at the last known valid RECIST v.1.1 response assessment.
Secondary end points included ORR, duration of response and median overall survival (OS). ORR per RECIST v1.1 [13] was computed by adding patients with confirmed complete response and confirmed partial response. The ORR among patients treated with CRLX101 þ bevacizumab versus SOC was compared using one-sided Cochran-Mantel-Haenszel test controlling for stratification factors. Patients without response data were counted as nonresponders for the intention-to-treat analysis. Median OS was obtained from the Kaplan-Meier estimator of the survivor function for each arm. The comparison of median OS was performed using the same methods as for the primary analysis. Patients who were not known to have died at the time of analysis were censored at the day they were last known to be alive.
Results

Patients and treatment assignment
The first patient was enrolled 14 November 2014, data cutoff for this analysis was 2 August 2016. A total of 115 patients were randomized, 56 to the investigational arm, 59 to the SOC arm. Clinical characteristics are summarized in 
Efficacy results
Of 115 randomized patients 111 received treatment on study (CRLX101 þ bevacizumab n ¼ 55 versus SOC n¼ 56); at the time of data cutoff nine patients (7.8%) remained on treatment. SOC regimens included axitinib (n ¼ 18), bevacizumab monotherapy (n ¼ 19), everolimus (n ¼ 7), pazopanib (n ¼ 4), Sorafenib (n ¼ 4), sunitinib (n ¼ 2) and temsirolimus (n ¼ 2). The distribution within the intention-to-treat and clear cell population of SOC patients is summarized in supplementary Table S1 , available at Annals of Oncology online.
The primary end point analysis of PFS based on blinded IRR assessment included 102 ccRCC patients and is summarized in Figure 1 . Thirty-five patients had a PFS event in the CRLX101 þ bevacizumab group (70.0%) versus 38 SOC patients (73.1%). Median PFS for 50 patients receiving CRLX101 þ bevacizumab was 3.7 months [95% CI (confidence 
The ORR among ccRCC, per blinded IRR assessment, was 4.8% for CRLX101 þ bevacizumab and 14.0% for t SOC (see also Table 2 ). This numerical difference was not statistically significant on Mantel-Haenszel test when correcting for lines of prior therapy and prior exposure to rapalog therapy (P ¼ 0.836). Similarly, duration of response did not differ (stratified log-rank P ¼ 0.404).
At the time of the data cutoff, 56 patients were in survival follow-up. For ccRCC patients the median OS was 16.1 months (95% CI 12.0 to not evaluable) on CRLX101 þ bevacizumab and 16.4 months (95% CI 13.3 to not evaluable) for SOC (stratified log-rank P ¼ 0.671; Cox proportional hazards model HR, 1.21; 95% CI 0.63-2.36; P ¼ 0.718; see Figure 2 ).
Several subgroup analyses were undertaken: outcomes were comparable for 13 patients with non-clear cell variants who achieved a median PFS of 2.8 versus 4.7 months with CRLX101þ bevacizumab versus SOC; the corresponding ORR was 0% on both treatment arms. When comparing 50 ccRCC patients treated with CRLX101 þ bevacizumab with 17 ccRCC SOC patients having received bevacizumab monotherapy, median PFS was comparable (3.7 versus 3.4 months; Cox proportional hazards model HR, 1.14; 95% CI 0.56-2.34; P ¼ 0.645; see also sup plementary Figure S1 , available at Annals of Oncology online ).
Safety and tolerability
Fifty-five patients received a median number of 5 CRLX101 þ bevacizumab infusions (range, 1-33) with 88% relative dose intensity and 2.8 months median treatment duration (2.9 months for SOC). Recurrent treatment emergent adverse events (AEs) for 111 patients are summarized in Table 3 . The incidence of grade 3þ treatment emergent AEs (TEAEs) (CRLX101 þ bevacizumab: 50.9%; SOC: 46.4%, respectively) and AEs leading to treatment discontinuation (14.5% and 12.5%) was comparable. The most common events for CRLX101 þ bevacizumab included fatigue (41.8%), nausea (36.4%) and constipation (32.7%), decreased appetite (23.6%), and headache (21.8%). In the SOC group, the most commonly reported TEAEs (>20%) were fatigue (44.6%), diarrhoea (30.4%), nausea (26.8%), and hypertension (25.0%). Nine patients experienced episodes of grade 2 cystitis, all assigned to CRLX101 þ bevacizumab (16%). One patient experienced a serious AE of cystitis that led to treatment discontinuation. Recurrent grade 3/4 treatment-related events for CRLX101 þ bevacizumab included fatigue (9.1%), hypertension (7.3%), anemia (5.5%), back pain (5.5%), abdominal pain (3.6%), and headache (3.6%). The incidence of grade 5 TEAEs was similar between groups (3.6% in the CRLX101 þ bevacizumab group and 5.4% in the SOC group). The only fatal AE assessed by the investigator as possibly related to study drug, sudden death, occurred in a patient in the CRLX101 þ bevacizumab group in the setting of multiple confounding variables. CRLX101+Bev 50 (0) 52 (0) 45 (1) 45 (1) 36 (9) 43 (3) 22 (18) 18 (21) 24 (21) 11 (27) 11 (27) 10 (28) 9 (28) 6 (30) 6 (30) 3 (33) 2 (34) 2 (34) 2 (34) 2 (34) 2 (34) 0 (35) 0 (38) 1 (38) 1 (38) 2 (38) 2 (38) 5 (36) 5 (36) 6 (36) 7 (35) 10 (33) 11 (32) 14 (29) 17 (26) 29 (17) At the time of data cut-off, 93% of the patients had discontinued study treatment in the CRLX101 þ bevacizumab and SOC groups (94.6% and 91.5%, respectively), 12 due to AEs (8.9% and 11.9%, respectively), and death (5.4% and 5.1%, respectively).
Discussion
Acquired resistance to standard TKI therapy is thought to be mediated by tumor angiogenesis via VEGF-independent escape pathways, a key mechanism being compensatory upregulation of Progression-free survival is calculated from randomization to the time of disease progression, death, or censoring: (date of progressive disease/death/censoring -randomization date þ 1)/7. a The log-rank test is stratified by two versus three prior lines of therapy and prior mTOR versus no prior mTOR. The overall response among patients treated with CRLX101 þ bevacizumab versus patients treated with SOC is compared using an exact one-sided Mantel-Haenszel test for the common odds ratio controlling for two versus three prior lines of therapy and prior mTOR versus no prior mTOR. CR, complete response; PR, partial response. 52 (0) 48 (1) 49 (1) 46 (3) 43 (5) 43 (5) 40 (7) 38 (7) 35 (10) 33 (10) 32 (11) 27 (13) 23 (14) 20 (14) 17 (14) 15 (15) 16 (16) 11 (15) 12 (17) 7 (17) 8 (17) 4 (17) 5 (17) 2 (18) 4 (18) 1 (18) 1 (18) 0 (18) 0 (18) 0 (18) 1 (18) 1 (18) 3 (18) 22 (16) 25 (16) 28 (15) 33 (14) 38 (11) 38 (11) 38 (11) 40 (9) 43 (7) 45 (5) 48 (2) 49 (1) SOC Figure 2 . Overall survival (weeks): Kaplan-Meier survival function estimates clear cell renal cell carcinoma patients randomized to CRLX101 þ bevacizumab versus standard of care. SOC, standard of care. Overall survival is calculated from randomization to the time of death for any reason or censoring: (date of death/censoring -randomization date þ 1)/7. Open circles represent censored events.
other HIF targets. This concept was exploited successfully in the development of the multitarget TKI cabozantinib [14] , which inhibits not only VEGFR but also the HIF targets AXL and MET, previously determined to be mediators of VEGF inhibitor resistance [15] . Further, the recent approval of lenvatinib plus everolimus supports the notion that combination approaches can prove beneficial in the setting of acquired resistance to TKI therapy [16] . Bevacizumab is well established as a partner for targeted combinations in RCC [17] . The combination of CRLX101 and bevacizumab makes use of the fact that CRLX101 through its payload's effects on topoisomerase-1 and via the enhanced permeability and retention properties of its nanoparticle delivery system is deemed to achieve extended inhibition of HIF1a protein accumulation via topoisomerase inhibition in tumor tissue [5, 7, 18] .
An investigator initiated trial had first tested the combination of CRLX101 plus bevacizumab in 27 RCC patients with manageable safety and promising efficacy [12] . This seemed pronounced in heavily pretreated patients (18 subjects with 2þ prior lines achieved an ORR of 22% with median PFS of 7.6 months), which prompted the design of the current trial targeting the third-and fourth-line setting. The decision to compare to SOC per investigators' discretion owed to the lack of dedicated standards in this space. Ultimately, the randomized design helped to make a lack of synergism apparent. We found similar efficacy for the investigational (ORR, 4.8%; median PFS 3.7 months) and the SOC arm (ORR 14% and median PFS 3.9 months). In fact, the efficacy observed for CRLX101 þ bevacizumab in patients with ccRCC was comparable to bevacizumab alone (3.7 versus 3.4 months; stratified log-rank P ¼ 0.268; supplementary Figure  S1 , available at Annals of Oncology online). In re-evaluating the encouraging findings of the prior phase I study, one must consider well-known effects of a single-center study conduct, which may have had relevant implications for patient selection, toxicity Treatment-emergent is defined as any AE with onset or worsening of a pre-existing condition after the administration of study medication through 30 days after the last dose, or any event considered drug-related by the Investigator through the end of the study. For each level of summarization, a patient contributes only once to the count for a given AE on the system organ class level and on the preferred term within system organ class level.
a Adverse events are classified by preferred term using MedDRA, Version 17.0. AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities.
management, and efficacy assessment. Finally, it is reassuring to see that the SOC arm produced similar efficacy to historical controls. A useful study in this regard was the Global Oncologic Learnings for Dovitinib (GOLD), NCT01223027 trial, a randomized study comparing dovitinib to sorafenib in the third line, which reported very comparable effects, including a median PFS of 3.7 months for dovitinib versus 3.6 months for sorafenib [4] . Toxicity was manageable and consistent with the phase I experience [12] . The addition of rigorous hydration pre-and post-CRLX101 decreased the incidence of noninfectious cystitis (37% on the prior phase I study [12] versus 12.7% across the primary efficacy population on the present trial). This trial's design sets an important precedent for using a 'SOC' comparator arm in the third-/fourth-line setting, where no defined standard lends itself readily for comparison. With a growing number of approved RCC regimens in the post-TKI space, this approach should be considered when studying novel therapies in more heavily pretreated patients.
In conclusion, this trial did not demonstrate added benefit for the combination of CRLX101 plus bevacizumab when compared with approved targeted agents in the third-/fourth-line setting. Further development of CRLX101 will focus on topoisomerase 1-sensitive tumors such as ovarian or gastrointestinal tumors.
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